Rankings
▼
Calendar
IBRX FY 2025 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena
IBRX
ImmunityBio, Inc.
$8B
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$113M
+668.3% YoY
Gross Profit
$113M
99.3% margin
Operating Income
-$256M
-226.0% margin
Net Income
-$351M
-310.2% margin
EPS (Diluted)
$-0.38
Cash Flow
Operating Cash Flow
-$305M
Free Cash Flow
-$305M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$502M
Total Liabilities
$1.0B
Stockholders' Equity
-$500M
Cash & Equivalents
$88M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$113M
$15M
+668.3%
Gross Profit
$113M
$15M
+663.2%
Operating Income
-$256M
-$344M
+25.6%
Net Income
-$351M
-$414M
+15.0%
← Q4 2024
All Quarters
Q1 2025 →